APA (7th ed.) Citation

Y, S., Y, L., D, Z., Y, C., S, M., M, W., . . . X, H. (2026). Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: A real-world propensity score-matched study. Frontiers in immunology, 17, 1808956. https://doi.org/10.3389/fimmu.2026.1808956

Chicago Style (17th ed.) Citation

Y, Su, Liang Y, Zhong D, Chen Y, Ma S, Wang M, Yang Q, Yan H, and Huang X. "Hepatitis B Virus Infection and Outcomes of TACE Plus Lenvatinib and PD-1 Inhibitor Therapy in Unresectable Hepatocellular Carcinoma: A Real-world Propensity Score-matched Study." Frontiers in Immunology 17 (2026): 1808956. https://doi.org/10.3389/fimmu.2026.1808956.

MLA (9th ed.) Citation

Y, Su, et al. "Hepatitis B Virus Infection and Outcomes of TACE Plus Lenvatinib and PD-1 Inhibitor Therapy in Unresectable Hepatocellular Carcinoma: A Real-world Propensity Score-matched Study." Frontiers in Immunology, vol. 17, 2026, p. 1808956, https://doi.org/10.3389/fimmu.2026.1808956.